We narrowed to 20,074 results for: INO

#137153-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-NpHR3.3-EYFP (#137153). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-NpHR3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of NpHR3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#51669-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-FlpO-bGHpA (#51669). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-FlpO-bGHpA plasmid DNA. hSyn-driven FlpO expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Oct. 28, 2021

Academic Institutions and Nonprofits only

#137161-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChRmine-oScarlet (#137161). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChRmine-oScarlet plasmid DNA. nEF-driven expression of ChRmine-oScarlet in the presence of Cre (inhibited in the presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Oct. 14, 2020

Academic Institutions and Nonprofits only

#137163-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#137149-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP (#137149). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of Arch3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#137143-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (#137143). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-mCherry plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-mCherry for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 25, 2021

Academic Institutions and Nonprofits only

#137148-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP (#137148). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of Arch3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#137150-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-Arch3.3-p2a-EYFP (#137150). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-Arch3.3-p2a-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of Arch3.3-EYFP (inhibited in presence of Cre) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#137140-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP (#137140). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2(E123T/T159C)-EYFP (inhibited in presence of Flp) for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#137164-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-nEF-Con/Fon/Von eYFP (#137164). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon/Von eYFP plasmid DNA. nEF-driven, Cre, Flp and VCre-dependent expression of EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 12, 2020

Academic Institutions and Nonprofits only